Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Novo Nordisk A/S grew revenues 4.04% from 122.02bn to 126.95bn while net income improved 8.18% from 38.95bn to 42.14bn.
Gross margin82.89%
Net profit margin34.31%
Operating margin41.74%
Return on assets29.41%
Return on equity73.49%
Return on investment59.69%
More ▼

Cash flow in DKKView more

In 2020, cash reserves at Novo Nordisk A/S fell by 3.19bn. However, the company earned 51.95bn from its operations for a Cash Flow Margin of 40.92%. In addition the company used 22.44bn on investing activities and also paid 32.24bn in financing cash flows.
Cash flow per share22.29
Price/Cash flow per share24.52
Book value per share29.10
Tangible book value per share20.06
More ▼

Balance sheet in DKKView more

Novo Nordisk A/S has a Debt to Total Capital ratio of 17.22%, a higher figure than the previous year's 4.42%.
Current ratio1.03
Quick ratio0.8187
Total debt/total equity0.208
Total debt/total capital0.1722
More ▼

Growth rates in DKK

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.98% and 9.97%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)2.47%
Div growth rate (5 year)7.29%
Payout ratio (TTM)35.64%
EPS growth(5 years)5.89
EPS (TTM) vs
TTM 1 year ago
12.96
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.